Trial Profile
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Sep 2020
Price :
$35
*
At a glance
- Drugs Demcizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 11 Oct 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
- 28 Apr 2011 Planned end date changed from 1 Nov 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 28 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.